3,4-DAA

• Description :

  3,4-DAA is an orally active Anthranilic acid derivative with potent immunosuppressive activities. 3, 4-DAA can alleviate the severity of colitis through inhibiting Th1 cells response, promoting Th2 cytokines expression and inducing CD4+CD25+ T cells expression[1]. 3,4-DAA suppressed expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) release from EOC20 cells induced by IFN-γ and Lipopolysaccharide[2].

• CAS Number :

  [2117759-07-4]

• UNSPSC :

  12352005

• Target :

  NO Synthase

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/3-4-daa.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(C1=C(NC(/C=C/C2=CC=C(C(OC)=C2)OC)=O)C(O)=CC=C1)O

• Molecular Formula :

  C18H17NO6

• Molecular Weight :

  343.33

• References & Citations :

  [1]Quan Wen, et al. N- (3', 4'-dimethoxycinnamonyl) anthranilic acid alleviated experimental colitis by inhibiting autoimmune response and inducing CD4+ CD25+ regulatory T cells production. J Gastroenterol Hepatol. 2013 Aug;28 (8) :1330-8.|[2]Michael Platten, et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science. 2005 Nov 4;310 (5749) :850-5.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported